13F reference period
Q2 2026
Security Snapshot
Evommune, Inc. - COMMON STOCK (EVMN) Institutional Ownership
CUSIP: 30054Y107
13F Institutional Holders and Ownership History from Q4 2025 to Q3 2026
Institutions Reporting
104
Shares (Excl. Options)
34.57M
Full value: 34,570,369 · shares · 30 Jun 2026Price
$13.29
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- EVMN on NYSE
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 34,570,369
- Total 13F value
- $462,177,708
- Portfolio coverage rank
- 0%
- Share change
- +1,143,265
- Value change
- -$34,339,695
- Number of holders
- 104
- Shares outstanding
- 35,943,315
- SEC-reported price per share
- $8.26
- Insider filing price
- $8.26
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- EVMN - Evommune, Inc. - COMMON STOCK is tracked under CUSIP 30054Y107.
- 104 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 84 to 104 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$793.41M
Full value: $793,406,919 · USD · 31 Mar 2026.$462.18M
Full value: $462,177,708 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 104 institutions filings for Q2 2026.
Security key
30054Y107
13F reference period
Q2 2026
13F holders
104
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
EVMN full holder history
Evommune, Inc. SEC filings
Evommune, Inc. company facts
Evommune, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 30054Y107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
EVMN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| LSP 7 Cooperative UA | 15% | -6.2% | $114,491,976 | +$7,765,422 | 5,288,313 | +7.3% | LSP 7 Cooperatieve U.A. | 12 Feb 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 9.7% | -12% | $70,347,063 | +$722,023 | 3,494,638 | +1% | RA Capital Management, L.P. | 12 Feb 2026 |
| Pivotal bioVenture Partners Fund I, L.P. | 11% | $69,158,608 | 3,435,599 | Nan Fung Group Holdings Limited | 31 Dec 2025 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.4% | $23,990,006 | 1,940,939 | T. Rowe Price Associates, Inc. | 30 Jun 2026 | |||
| Point72 Asset Management, L.P. | 5.3% | $25,391,927 | 1,910,489 | Point72 Asset Management, L.P. | 15 Jul 2026 | |||
| Andera Partners | 3.9% | -35% | $17,204,996 | -$6,246,398 | 1,391,990 | -27% | Andera Partners | 30 Jun 2026 |
As of 30 Jun 2026,
104
institutional investors reported holding
shares of
Evommune, Inc. - COMMON STOCK (EVMN).
This represents
96%
of the company’s total
outstanding shares.
34.57M
Full value: 34,570,369 · shares · 30 Jun 202635.94M
Full value: 35,943,315 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
85%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 15% | 5,288,313 | +7.3% | 8.1% | $70,281,680 |
| RA CAPITAL MANAGEMENT, L.P. | 9.7% | 3,494,638 | 0% | 0.4% | $46,443,739 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.4% | 1,940,939 | +73% | 0% | $25,796,000 |
| Pivotal bioVenture Partners Investment Advisor LLC | 5.4% | 1,926,943 | 0% | 8.3% | $25,609,072 |
| JPMORGAN CHASE & CO | 4.3% | 1,553,132 | +6.4% | 0% | $23,374,637 |
| RTW INVESTMENTS, LP | 4.2% | 1,502,235 | 0% | 0.17% | $19,964,703 |
| Nan Fung Group Holdings Ltd | 4% | 1,441,032 | 0% | 15% | $19,151,315 |
| Point72 Asset Management, L.P. | 4% | 1,435,049 | +3823% | 0.03% | $19,071,801 |
| ANDERA PARTNERS | 3.9% | 1,391,990 | -27% | 9% | $18,499,547 |
| EVENTIDE ASSET MANAGEMENT, LLC | 3.4% | 1,209,129 | 0% | 0.21% | $16,069,325 |
| Vestal Point Capital, LP | 2.8% | 1,000,000 | 0.31% | $13,290,000 | |
| Jupiter Topco LLC | 2.5% | 896,700 | 0% | 0% | $11,917,143 |
| BlackRock, Inc. | 2.5% | 886,538 | +32% | 0% | $11,782,090 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 881,895 | +94% | 0% | $11,720,385 |
| BAKER BROS. ADVISORS LP | 2.4% | 847,390 | 0% | 0.06% | $11,261,813 |
| Defilade Capital Management, L.P. | 2.2% | 793,145 | +17% | 1.4% | $10,540,897 |
| AMERICAN CENTURY COMPANIES INC | 2.1% | 755,018 | +53% | 0% | $10,034,211 |
| Alyeska Investment Group, L.P. | 2% | 704,425 | -3% | 0.02% | $9,361,808 |
| Balyasny Asset Management L.P. | 1.3% | 457,015 | 0.01% | $6,073,729 | |
| Velan Capital Investment Management LP | 1.3% | 451,255 | +1.1% | 3.7% | $5,997,179 |
| UBS Group AG | 1.2% | 413,553 | +39% | 0% | $5,496,119 |
| GREAT POINT PARTNERS LLC | 0.9% | 325,000 | 0% | 1% | $4,319,250 |
| FEDERATED HERMES, INC. | 0.9% | 325,000 | 0% | 0.01% | $4,319,250 |
| Freestone Grove Partners LP | 0.85% | 306,328 | -9.2% | 0.03% | $4,071,099 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.84% | 301,759 | +21% | 0% | $4,011,321 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
4
Headline period
Q2 2026
Rows shown
1-4 of 4
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 257,614 | $2,127,892 | -$9,927,165 | $8.26 | 9 |
| 2026 Q2 | 34,570,369 | $462,177,708 | -$34,339,695 | $13.29 | 104 |
| 2026 Q1 | 34,576,739 | $793,406,919 | +$167,246,545 | $22.99 | 84 |
| 2025 Q4 | 27,200,904 | $465,685,578 | +$403,679,610 | $17.12 | 59 |